Annexon (ANNX) Competitors $2.55 +0.07 (+2.82%) Closing price 07/24/2025 04:00 PM EasternExtended Trading$2.58 +0.03 (+1.14%) As of 08:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANNX vs. GHRS, AKBA, SANA, ZYME, COLL, SYRE, RCUS, VERV, AMPH, and AVXLShould you be buying Annexon stock or one of its competitors? The main competitors of Annexon include GH Research (GHRS), Akebia Therapeutics (AKBA), Sana Biotechnology (SANA), Zymeworks (ZYME), Collegium Pharmaceutical (COLL), Spyre Therapeutics (SYRE), Arcus Biosciences (RCUS), Verve Therapeutics (VERV), Amphastar Pharmaceuticals (AMPH), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry. Annexon vs. Its Competitors GH Research Akebia Therapeutics Sana Biotechnology Zymeworks Collegium Pharmaceutical Spyre Therapeutics Arcus Biosciences Verve Therapeutics Amphastar Pharmaceuticals Anavex Life Sciences Annexon (NASDAQ:ANNX) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Which has better valuation and earnings, ANNX or GHRS? GH Research is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$138.20M-$1.18-2.16GH ResearchN/AN/A-$38.96M-$0.79-18.34 Does the media favor ANNX or GHRS? In the previous week, GH Research had 4 more articles in the media than Annexon. MarketBeat recorded 6 mentions for GH Research and 2 mentions for Annexon. GH Research's average media sentiment score of 0.57 beat Annexon's score of 0.29 indicating that GH Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GH Research 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in ANNX or GHRS? 56.9% of GH Research shares are owned by institutional investors. 11.9% of Annexon shares are owned by insiders. Comparatively, 41.6% of GH Research shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is ANNX or GHRS more profitable? GH Research's return on equity of -19.20% beat Annexon's return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -54.45% -46.56% GH Research N/A -19.20%-18.40% Do analysts rate ANNX or GHRS? Annexon currently has a consensus target price of $12.50, indicating a potential upside of 390.20%. GH Research has a consensus target price of $32.00, indicating a potential upside of 120.84%. Given Annexon's higher possible upside, equities research analysts clearly believe Annexon is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ANNX or GHRS? Annexon has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. SummaryGH Research beats Annexon on 9 of the 12 factors compared between the two stocks. Get Annexon News Delivered to You Automatically Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANNX vs. The Competition Export to ExcelMetricAnnexonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$272.09M$3.05B$5.72B$9.47BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-2.1620.8627.9419.95Price / SalesN/A317.05452.94100.82Price / CashN/A43.2336.5558.97Price / Book0.938.308.645.90Net Income-$138.20M-$55.19M$3.24B$258.42M7 Day Performance9.91%5.81%3.69%2.11%1 Month Performance6.69%17.73%10.33%12.44%1 Year Performance-58.70%4.67%34.30%19.55% Annexon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANNXAnnexon2.3702 of 5 stars$2.55+2.8%$12.50+390.2%-58.1%$272.09MN/A-2.1660Gap UpGHRSGH Research2.0984 of 5 stars$19.50+11.0%$32.00+64.1%+22.8%$1.01BN/A-24.6810AKBAAkebia Therapeutics3.8477 of 5 stars$3.84-0.5%$6.75+75.8%+161.2%$1.01B$160.18M0.00430Positive NewsSANASana Biotechnology3.2338 of 5 stars$4.44-4.1%$9.17+106.5%-16.2%$1.00BN/A-5.05380Gap UpZYMEZymeworks2.9581 of 5 stars$14.32+0.5%$21.00+46.6%+34.7%$997.86M$93.38M-9.55460Upcoming EarningsCOLLCollegium Pharmaceutical4.4785 of 5 stars$30.91-0.9%$43.75+41.5%-6.5%$993.14M$631.45M25.34210Positive NewsSYRESpyre Therapeutics2.5426 of 5 stars$16.35+0.4%$53.40+226.6%-42.7%$985.58M$890K-4.3473Positive NewsRCUSArcus Biosciences1.6818 of 5 stars$9.27+1.3%$21.29+129.7%-32.2%$981.18M$258M-2.21500VERVVerve Therapeutics2.9104 of 5 stars$10.93+0.2%$14.57+33.3%+57.2%$974.30M$32.33M-5.18110News CoverageAMPHAmphastar Pharmaceuticals4.4658 of 5 stars$21.19+2.8%$32.33+52.6%-45.4%$972.01M$731.97M6.532,028AVXLAnavex Life Sciences4.0078 of 5 stars$11.16+1.6%$44.00+294.3%+97.2%$953.29MN/A-20.2940Positive News Related Companies and Tools Related Companies GHRS Competitors AKBA Competitors SANA Competitors ZYME Competitors COLL Competitors SYRE Competitors RCUS Competitors VERV Competitors AMPH Competitors AVXL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANNX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANNX Stock Alerts